These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 23252955)

  • 1. A centralized approach to out-of-province genetic testing leads to cost savings: the Alberta experience.
    Lilley M; Christian S; Blumenschein P; Chan S; Somerville M
    Clin Genet; 2013 Oct; 84(4):373-7. PubMed ID: 23252955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost savings associated with improving appropriate and reducing inappropriate preventive care: cost-consequences analysis.
    Hogg W; Baskerville N; Lemelin J
    BMC Health Serv Res; 2005 Mar; 5(1):20. PubMed ID: 15755330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An assessment of Canadian systems for triaging referred out genetic testing.
    Christian S; Blumenschein P; Lilley M
    Clin Genet; 2015 Jul; 88(1):90-4. PubMed ID: 25065508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An Electronic Strategy for Eliminating Unnecessary Duplicate Genetic Testing.
    Riley JD; Stanley G; Wyllie R; Burt HL; Horwitz SB; Cooper DD; Procop GW
    Am J Clin Pathol; 2020 Feb; 153(3):328-332. PubMed ID: 31665226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An Economic Evaluation of the National Surgical Quality Improvement Program (NSQIP) in Alberta, Canada.
    Thanh NX; Baron T; Litvinchuk S
    Ann Surg; 2019 May; 269(5):866-872. PubMed ID: 29465460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reuse and refurbish: a cost savings delivery model for specialized seating.
    Li Pi Shan RS; Chrusch WM; Linassi AG; Sankaran R; Munchinsky J
    Arch Phys Med Rehabil; 2012 Jul; 93(7):1286-8. PubMed ID: 22410182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2.
    Gilchrist DM; Morrish DW; Bridge PJ; Brown JL
    Clin Genet; 2004 Oct; 66(4):349-52. PubMed ID: 15355438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is chromosome testing of the second miscarriage cost saving? A decision analysis of selective versus universal recurrent pregnancy loss evaluation.
    Bernardi LA; Plunkett BA; Stephenson MD
    Fertil Steril; 2012 Jul; 98(1):156-61. PubMed ID: 22516510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic testing: are family physicians ready?
    Weber R
    Am Fam Physician; 1996 May; 53(6):1976, 1978. PubMed ID: 8623707
    [No Abstract]   [Full Text] [Related]  

  • 10. Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective.
    Burgess ED; Carides GW; Gerth WC; Marentette MA; Chabot I;
    Can J Cardiol; 2004 May; 20(6):613-8. PubMed ID: 15152291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost savings associated with changes in routine laboratory tests ordered for victims of trauma.
    Jacobs IA; Kelly K; Valenziano C; Chevinsky AH; Pawar J; Jones C
    Am Surg; 2000 Jun; 66(6):579-84. PubMed ID: 10888135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in testing behaviours for hepatitis C virus infection and associated determinants: results from population-based laboratory surveillance in Alberta, Canada (1998-2001).
    Jayaraman GC; Lee B; Singh AE; Preiksaitis JK
    J Viral Hepat; 2007 Apr; 14(4):249-54. PubMed ID: 17381716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001.
    Krentz HB; Auld MC; Gill MJ;
    CMAJ; 2003 Jul; 169(2):106-10. PubMed ID: 12874156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Direct-to-patient BRCA1 testing: the Twoj Styl experience.
    Gronwald J; Huzarski T; Byrski T; Debniak T; Metcalfe K; Narod SA; Lubiński J
    Breast Cancer Res Treat; 2006 Dec; 100(3):239-45. PubMed ID: 16807675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Familial paraganglioma syndrome: applying genetic screening in otolaryngology.
    Dziegielewski PT; Knox A; Liu R; Hung RW; Harris J
    J Otolaryngol Head Neck Surg; 2010 Dec; 39(6):646-53. PubMed ID: 21144359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of the familial cancer programme in Western Australia: predictive genetic testing for familial adenomatous polyposis and hereditary non-polyposis colorectal carcinoma.
    Breheny N; Geelhoed E; Goldblatt J; Ee H; O'Leary P
    Community Genet; 2006; 9(2):98-106. PubMed ID: 16612060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assisted Reproductive Technologies in Alberta: An Economic Analysis to Inform Policy Decision-Making.
    Vaidya A; Stafinski T; Nardelli A; Motan T; Menon D
    J Obstet Gynaecol Can; 2015 Dec; 37(12):1122-30. PubMed ID: 26637087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. United HealthCare buys Humana.
    Integr Healthc Rep; 1998 Apr; ():7. PubMed ID: 10180269
    [No Abstract]   [Full Text] [Related]  

  • 19. Cost analysis for decision support: the case of comparing centralized versus distributed methods for blood gas testing.
    Kilgore ML; Steindel SJ; Smith JA
    J Healthc Manag; 1999; 44(3):207-15. PubMed ID: 10537498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inappropriate repeat testing of complete blood count (CBC) and electrolyte panels in inpatients from Alberta, Canada.
    Kandalam V; Lau CK; Guo M; Ma I; Naugler C
    Clin Biochem; 2020 Mar; 77():32-35. PubMed ID: 31891680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.